Skip to main content

MANIPULACION DE LA INFLAMACION COMO ESTRATEGIA PARA INDUCIR TOLERANCIA INMUNOLÓGICA: HACIA UNA INMUNOTERAPIA PERSONALIZADA EN ENFERMEDADES AUTOINMUNES CRÓNICAS

PI21/00944

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis

  • Fondelli, Federico|||0000-0002-6875-4744
  • Willemyns, Jana|||0000-0001-6325-9309
  • Domenech-Garcia, Roger|||0009-0002-5742-566X
  • Mansilla, Maria José
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Ferreté-Bonastre, Anna G.|||0000-0003-3327-6129
  • Agúndez-Moreno, Alex|||0009-0000-9524-235X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Multiple sclerosis (MS) is a chronic disease characterized by dysregulated self-reactive immune responses that damage the neurons' myelin sheath, leading to progressive disability. The primary therapeutic option, immunosuppressants, inhibits pathogenic anti-myelin responses but depresses the immune system. Antigen-specific monocyte-derived autologous tolerogenic dendritic cells (tolDCs) offer alternative therapeutic approaches to restore tolerance to autoantigens without causing generalized immunosuppression. However, immune dysregulation in MS could impact the properties of the monocytes used as starting material for this cell therapy. Here, we characterized CD14+ monocytes, mature dendritic cells, and vitamin D3-tolDCs (VitD3-tolDCs) from active, treatment-naive MS patients and healthy donors (HDs). Using multiomics, we identified a switch in these cell types toward proinflammatory features characterized by alterations in the aryl hydrocarbon receptor (AhR) and NF-κB pathways. MS patient-derived VitD3-tolDCs showed reduced tolerogenic properties compared with those from HDs, which were fully restored through direct AhR agonism and by use of in vivo or in vitro dimethyl fumarate (DMF) supplementation. Additionally, in the experimental autoimmune encephalomyelitis mouse model, combined therapy of DMF and VitD3-tolDCs was more efficient than monotherapies in reducing the clinical score of mice. We propose that a combined therapy with DMF and VitD3-tolDCs offers enhanced therapeutic potential in treating MS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of cognitive rehabilitation in cognition and brain networks, A randomised clinical trial in patients with multiple sclerosis

  • Lopez-Soley, Elisabet
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Vivó Pascual, Francesc|||0000-0002-6409-1197
  • Calvi, Alberto|||0000-0002-1953-2803
  • Alba-Arbalat, Salut|||0000-0003-1662-2317
  • Romero Pinel, Lucía|||0000-0001-8054-0565
  • Martínez Yélamos, Sergio|||0000-0001-9889-2040
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Munteis, Elvira|||0000-0002-6195-9106
  • Martínez-Rodríguez, José Enrique
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Anglada, E.|||0000-0001-5074-4970
  • Meza-Murillo, Edwin Roger|||0000-0001-6065-3546
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Sánchez Carrión, Rocío
  • Pelayo, Raúl|||0000-0002-1313-0686
  • Bernabeu Guitart, Montserrat|||0000-0003-2037-3069
  • Sola-Valls, Nuria
  • Hervas, M.
  • Sepúlveda, María
  • Saiz, Albert|||0000-0002-5793-8791
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
This study evaluated the efficacy of the computerised Guttmann, NeuroPersonalTrainer® (GNPT) cognitive rehabilitation (CR) and characterised the induced changes in cerebral networks in patients with multiple sclerosis (MS). This multicentre, double-blind, randomised clinical trial compared upward intensity training (active treatment) to low-intensity static training (static treatment). Cognition was assessed using the Brief Repeatable battery before and after 12 weeks of training and at 10-months follow-up, and patients were classified as having a mild or severe cognitive impairment (CI). Brain MRI pre- and post-CR were analysed using an advanced tractography algorithm, based on multishell diffusion MRI, to obtain node-based graph metrics (local efficiency and strength) from microscopic fractional anisotropy. Seventy MS patients completed the study (age 48.9 ± 8.8, disease duration 16.8 ± 9.0 years); active treatment: 36, static treatment: 34. Verbal memory improved significantly post-CR in both groups (55 % active; 34 % static treatment), accompanied by increases in local efficiency and strength in multimodal regions. At follow-up, verbal memory declined in both groups but remained above the pre-CR assessment (-25 % and -17 %, respectively). Patients with severe-CI (n = 36) showed improvement only with active treatment, while those with mild-CI (n = 34) improved regardless of intensity treatment. Network changes were more pronounced in patients in active treatment and in those with severe-CI. Quality of life did not change at post-CR, and cognitive improvement was influenced by cognitive reserve (p = 0.011). In MS, GNPT temporarily improves verbal memory and increases network connectivity, reinforcing the CR as a valuable tool for enhancing cognitive skills and promoting neuronal plasticity.